Feature | Heart Valve Technology | July 01, 2015

CardiAQ Valve Technologies Reports First-in-Human Implantation with Second Generation Transcatheter Bioprosthetic Mitral Heart Valve

Self-conforming, self-anchoring device implanted in 72-year-old male with severe mitral regurgitation in Rome

CardiAQ Valve Technologies, TMVI, second generation, implantation, Tor Vergata

July 1, 2015 - CardiAQ Valve Technologies (CardiAQ) announced that its second-generation transcatheter bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment. The device was placed into a 72-year-old male suffering from severe mitral regurgitation (MR 4+) with multiple co-morbidities and ineligible for alternate treatment modalities.

The procedure was performed at the Tor Vergata Hospital in Rome, Italy, by an experienced heart team led by Director of Cardiology Francesco Romeo, M.D., and interventional cardiologist Gian Paolo Ussia, M.D., also including cardiac surgeon Giovanni Ruvolo, M.D., anesthesiologist Pasquale De Vico, M.D., and echocardiographer Valeria Cammalleri, M.D. Interventional cardiologist Lars Sondergaard, M.D., (Rigshospitalet, Copenhagen, Denmark) and cardiovascular surgeon and inventor of the CardiAQ TMVI technology Arshad Quadri, M.D., (St Francis Hospital, Hartford, CT) also participated.

"We have now performed three CardiAQ TMVI [transcatheter mitral valve implantation] cases (2 transapical and 1 transseptal) at Tor Vergata with excellent results, reducing the severe MR to trace and with no mitral or outflow tract gradients," said Ussia, who is primary investigator at the Rome Hospital. "We are convinced that these new procedures will in the future represent a substantial treatment improvement for our patients with mitral valve disease. Our heart team is excited to be a part of these groundbreaking clinical trials."

The CardiAQ device is a self-conforming, self-anchoring technology for nonsurgical transfemoral-transseptal percutaneous TMVI.

For more information: www.cardiaq.com

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init